https://www.selleckchem.com/products/vcmmae.html
Ustekinumab (UST) targets the common subunit (p4 of interleukins-12/23,1,2 approved for intravenous (IV) induction of remission in moderate-to-severe Crohn's disease (CD), followed by subcutaneous (SC) doses for maintenance of remission.3,4 The role of IV reinduction of UST in patients already on every-4-week (Q4) maintenance with partial response or loss of response (LOR) is unclear.5 The aim was to assess response and remission rates for UST IV reinduction in patients with CD with partial response or LOR who already were on Q4 SC dos
Like
Comment
Share
